The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

Sponsor
Hoffmann-La Roche
Study ID
NCT03559647
Status
Completed

Conditions

  • Non-Small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).

Study Details

Hyperion Is A Prospective, Multicenter, Non-Interventional, Two-Cohort Study Collecting Primary Data In Patients With Locally Advanced Or Metastatic NSCLC Of Squamous Or Non-Squamous Histology After Prior Chemotherapy Being Treated With Atezolizumab In Routine Clinical Practice.

Key Dates

Start date
May 30, 2018
Status verified
Aug 2023
Primary completion
Aug 20, 2023
Completion
Aug 20, 2023

Study Design

Enrollment
358 participants (actual)

Arms

  • Arm: Cohort 1
    Participants who have demonstrated a lack of Clinical Benefit from Atezolizumab
  • Arm: Cohort 2
    Participants who demonstrated durability of Clinical Benefit and Tumor Response to Atezolizumab

Primary Outcome Measure

Time to loss of clinical benefit (TTLCB) from Atezolizumab treatment [ Time Frame: Time from first dose to loss of clinical benefit as assessed by the treating physician, through the end of study (approximately 5 years). ]

Related Studies